

Hikma Pharmaceuticals PLC**(the "Company")**

LONDON, 19 December 2025: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces it has been notified of the following transactions by a Person Discharging Managerial Responsibilities ("PDMR") of the Company.

This notification is made under Article 19(1) of the EU Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided in accordance with the requirements of Article 19(3) of MAR.

Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities**Mazen Darwazah**

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Mazen Darwazah	
2	Reason for the notification		
a)	Position/status	Executive Vice Chairman	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Hikma Pharmaceuticals PLC	
b)	LEI	549300BNS685UXH4JI75	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083	
b)	Nature of the transaction	Purchase of Shares in Hikma Pharmaceuticals PLC	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.986	100,000
d)	Aggregated information	Price(s): £14.986 Volume(s): 100,000 Total: £1,498,580	
e)	Date of the transaction	19 December 2025	
f)	Place of the transaction	London Stock Exchange (XLON)	

Helen Middlemist
Group Company Secretary
+44 (0) 20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBUBDDGUBDGUC